Prothena Corporation plc (PRTA) Stock Analysis

Prothena Corporation plc (PRTA) is a publicly traded company in the HEALTHCARE sector. It trades at $9.19, carries a market capitalization of $502.07M. This page summarizes the public market data, fundamentals, and frequently asked questions for PRTA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Prothena Corporation plc currently has a Neutral sentiment score of 0.12.

About Prothena Corporation plc

Prothena Corporation plc is a clinical-stage biotechnology company based in Dublin, Ireland, focused on the discovery and development of innovative therapies for severe, life-threatening diseases. With a robust pipeline aimed at addressing disorders linked to protein misfolding, including Alzheimer's disease and other neurodegenerative conditions, Prothena is dedicated to meeting substantial unmet medical needs. Leveraging state-of-the-art scientific research and a strong portfolio of intelle...

GNG Research Analysis

GNG Research scores Prothena Corporation plc (PRTA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PRTA.

Frequently Asked Questions

Does PRTA pay dividends?

Prothena Corporation plc (PRTA) does not currently pay a regular dividend.

What is PRTA's market cap?

Prothena Corporation plc (PRTA) has a market capitalization of $502.07M with a current stock price of $9.19.